CTCO DD - as of 03/26/2014 The MJ Play!!!!  CT

CTCO DD - as of 03/26/2014


The MJ Play!!!!  CTCO -CANNABIS THERAPY CORP.



- CTCO is issing a Dividend! 0.5 for every share you own! Must be in by 03/28/2014

See 8k: http://www.otcmarkets.com/edgar/GetFilingHtml...ID=9876847

Current OS:
O/S: 46,875,331
Float: 23,819,333
A/S: ?

Following the Smith Share Cancellation we will have 46,875,331 shares issued and outstanding and the 25,055,998 shares will represent approximately 53.5% of our issued and outstanding shares.

See recent 8k dated March 14, 2014 item 5.01 on page 2:

http://www.otcmarkets.com/edgar/GetFilingHtml...ID=9857349

Who are the players?

Company Officers/Contacts

President, CEO

Soren Mogelsvang

PhD, Founder and VP of Research and Development
15 years experience in discovery and translational research from various positions in biotech and academia. Dr. Mogelsvang holds a Ph.D. degree from the University of Cambridge, England, and received postdoctoral training at the University of Colorado School of Medicine.

CFO, Secretary, Treasurer

Arnold Tinter

Was appointed as Director, Chief Financial Officer and Secretary on January 10, 2012. Mr. Tinter founded Corporate Finance Group, Inc., a consulting firm located in Denver, Colorado, in 1992, and is its President. Corporate Finance Group, Inc, is involved in financial consulting in the areas of strategic planning, mergers and acquisitions and capital formation. He provides Chief Financial Officer (CFO) services to a number of public companies, including Barfresh Food Group Inc., LifeApps Digital Media Inc. and Arvana Inc. From 2006 to 2010 he has provided CFO services to Spicy Pickle Franchising, Inc., a public company, where his responsibilities included oversight of all accounting functions, including SEC reporting, strategic planning and capital formation. From May 2001 to May 2003, he served as CFO of Bayview Technology Group, LLC, a privately held company that manufactured and distributed energy-efficient products. From May 2003 to October 2004, he served as that companys Chief Executive Officer. Prior to 1990 Mr. Tinter was Chief Executive Officer of Source Venture Capital, a holding company with investments in the gaming, printing, retail industries. Mr. Tinter currently serves as a director of Lifeapps Digital Media Inc., a public company. Mr. Tinter received a B.S. degree in Accounting in 1967 from C.W. Post College, Long Island University, and is licensed as a Certified Public Accountant in Colorado.

http://www.forbes.com/profile/arnold-tinter/

Company Directors:

Vered Caplan -

age 45, has been the Chief Executive Officer of Kamedis, a company focused on utilizing plant extracts for dermatology purposes since 2008. From 2004 to 2007, Ms. Caplan was Chief Executive Officer of GammaCan, a company focused on the use of immunoglobulins for the treatment of cancer. During the past five years, Ms. Caplan has been a director of the following companies: Opticul Ltd., a company involved with optic based bacteria classification; Inmotion Ltd., a company involved with self-propelled disposable colonoscopies; Nehora Photonics Ltd., a company involved with non-invasive blood monitoring; Ocure Ltd., a company involved with wound management; Eve Medical Ltd., a company involved with hormone therapy for Menopause and PMS; and Biotech Investment Corp., a company involved with prostate cancer diagnostics. Ms. Caplan has a M.Sc. in bio-medical engineering from Tel-Aviv University specialized in signal processing; management for engineers from Tel-Aviv University specialized in business development; and a B.Sc. in mechanical engineering from the Technion Institute of Technology specialized in software and cad systems.

http://www.kamedis.com/kamedis-worldwide.html

Dr. Cohava Gelber

Founder and Executive Chairperson
Over 25 years experience in various executive positions in biotech and pharmaceutical companies (ImmuLogic Pharmaceutical Corp., Molecular Discoveries, MannKind Corp.); drug discovery and product development experience from non clinical stages, IND, through clinical development up to phase III clinical trials; secured over $500MM of federal funding; authored over 70 patents/patent applications; PhD from the Weizmann Institute, Post Doctorate at Stanford University and MBA from Cornell University.

Guy Yachin

Engineer and MBA, President & CEO
Entrepreneur and CEO of multiple biomedical companies; raised ~$100MM as CEO and Co-founder of Chiasma (announced a 600MM deal with Roche in February 2013) and MGVS (led it through a mega-deal with Teva Pharmaceuticals); has been an active board member of several successful private and public companies, among them Orgenesis (ORGS), Enzymotec, Remon Medical (acquired by BSC) and NanoPass.

New Articles out:

http://www.crainsnewyork.com/article/20140326...es-to-pot#

http://www.stockhouse.com/news/natural-resour...o-next-gen

http://marijuanaindex.org/2014/03/cannabis-th...s-new-ceo/

http://www.biomedreports.com/20140324175106/c...f-ceo.html